Molecular profiling of mBRAFV600E mCRC summarized by Arndt Vogel

Arndt Vogel, Managing Senior Consultant and a Professor in the Department of Gastroenterology, Hepatology, and Endocrinology at Hannover Medical School, shared an article by Scott Kopetz on X:

“Molecular profiling of mBRAFV600E mCRC.

• BEACON phs-3.
• No impact of CMS, BM subtypes, GA (incl. RNF43), MSI or TMB on efficacy.
• more benefit w/ MEKi in immune-activated tumors?
• interesting analysis on acquired resistance mutations.”

Molecular profiling of BRAF-V600E-mutant metastatic colorectal cancer in the phase 3 BEACON CRC trial.

Authors: Scott Kopetz, et al.

Arndt Vogel, MD, is a Managing Senior Consultant and a Professor in the Department of Gastroenterology, Hepatology, and Endocrinology at Hannover Medical School. Leading the GI-Cancer Center and the Center for Personalized Medicine, his research focuses on translational and clinical studies in gastrointestinal cancer. He’s actively engaged in various societies including ESMO, ASCO, and EASL. Additionally, he chairs the Hepatobiliary Cancer Study Group of the AIO, contributing significantly to clinical oncology in Germany. Within ESMO, he serves on the Guidelines Steering Committee.